Home Print this page Email this page
Users Online: 107
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2020  |  Volume : 9  |  Issue : 4  |  Page : 322-328

Nanoparticle-based dry Powder Inhaler-Based Approach for Corona Virus Disease-2019 Treatment: An Update


1 Department of Pharmacology, Government Pharmacy Institute, Agam Kuan, Patna, Bihar, India
2 Department of P.G. Studies and Research in Chemistry and Pharmacy, Rani Durgavati University, Jabalpur, India
3 Department of Pharmaceutical Chemistry, Kailash Narayan Patel College of Pharmacy, Bhopal, Madhya Pradesh, India
4 Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, Madhya Pradesh, India

Correspondence Address:
Dr. Neeraj Mishra
Amity Institute of Pharmacy, Amity University Madhya Pradesh, Maharajpura, Gwalior - 474 005, Madhya Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijhas.IJHAS_93_20

Rights and Permissions

Corona virus disease-2019 (COVID 19) is a respiratory disorder caused by bunches of serious respiratory disorders (i.e., coughing, fever, and breathing problems) like severe acute respiratory syndrome (SARS), and the 79% homology as well as gene sequences are basically similar to SARS-CoV, thus the name of COVID-19 also be distinguish as SARS-CoV-2 on January 7th. Nanoparticles may also improve drug pulmonary efficacy by enhancing residence time, as a consequence the efficient mucus complexation between mucin and nanoparticles caused increment the rate of permeation and tissue uptake and displayed sustainable release property. Advances in device technology have led to the development of more efficient delivery systems capable of delivering larger doses and finer particles into the lung. As more efficient pulmonary delivery devices and sophisticated formulations become available, physicians, and health professionals will have a choice of a wide variety of device and formulation combinations that will target-specific cells or regions of the lung, avoid the lung's clearance mechanisms and be retained within the lung for longer periods. Dry powder inhalers (DPIs) exhibit many unique advantages that have contributed to the incredible growth in the number of DPI pharmaceutical products. To improve the performance, there are a relatively large number of DPI devices available for different inhalable powder formulations. The present review different type of nanoaparticles and DPIs used for the treatment of COVID 19 infections.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed263    
    Printed6    
    Emailed0    
    PDF Downloaded35    
    Comments [Add]    

Recommend this journal